PAVmed Inc.
PAVM Healthcare Medical Devices
PAVmed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71,000.00, down 97.6% from fiscal 2024. In the quarter to June 2026, revenue grew 450.0%, EPS grew 96.1% and free cash flow fell 125.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow PAVM
PAVmed Inc. (PAVM) EV/Sales
As of 16 October 2026, PAVmed Inc. (PAVM) trades at a EV/Sales of 236×. Over the past ten years it has ranged from −24.1× (December 2022) to 454× (July 2026); the current reading is higher than 94% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 88.0× | 3,102.87% |
| FY2024 | 2.7× | (48.29%) |
| FY2023 | 5.3× | (36.81%) |
| FY2022 | 8.4× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 434× | 50.50% |
| Mar 2026 | 288× | 227.21% |
| Dec 2025 | 88.0× | (73.19%) |
| Sep 2025 | 328× | 3,186.58% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MODD Modular Medical, Inc. compare | n/m |
| BDMD Baird Medical Investment Holdings Limited compare | n/m |
| ARAY Accuray Incorporated compare | 0.3× |
| LFWD Lifeward Ltd. compare | 0.9× |
| NSPR InspireMD, Inc. compare | 1.1× |
| PMI Flag Ship Acquisition Corp compare | 3.9× |
| ALUR Allurion Technologies, Inc. compare | 5.3× |
| PAVM PAVmed Inc. | 236× |
| HSCS HeartSciences Inc. compare | 556× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)